281 related articles for article (PubMed ID: 20173084)
1. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
Krishnan SM; Pennick M; Stark JG
Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
Krishnan S; Zhang Y
J Clin Pharmacol; 2008 Mar; 48(3):293-302. PubMed ID: 18285619
[TBL] [Abstract][Full Text] [Related]
7. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
[TBL] [Abstract][Full Text] [Related]
8. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
11. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
Krishnan SM; Stark JG
Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
[TBL] [Abstract][Full Text] [Related]
12. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Haffey MB; Buckwalter M; Zhang P; Homolka R; Martin P; Lasseter KC; Ermer JC
Postgrad Med; 2009 Sep; 121(5):11-9. PubMed ID: 19820270
[TBL] [Abstract][Full Text] [Related]
13. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Martin P; Dirks B; Gertsik L; Walling D; Stevenson A; Corcoran M; Raychaudhuri A; Ermer J
J Clin Psychopharmacol; 2014 Dec; 34(6):682-9. PubMed ID: 25310201
[TBL] [Abstract][Full Text] [Related]
15. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
Childress AC; Sallee FR
Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
[TBL] [Abstract][Full Text] [Related]
16. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
Ermer J; Corcoran M; Lasseter K; Martin PT
Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
[TBL] [Abstract][Full Text] [Related]
17. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
18. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
19. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
